Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1987 Jul;56(1):7–13. doi: 10.1038/bjc.1987.144

Immunogenic capacity of tum--variants isolated from a rat rhabdomyosarcoma.

C Pauwels-Vergely, M F Poupon
PMCID: PMC2001667  PMID: 2956985

Abstract

An increasing number of reports highlight the fact that tumour cells are able to give rise in vitro to immunogenic variants, which are defined in vivo as being non tumorigenic, tum-. We have observed the emergence of immunogenic variants, derived from a primary nickel-induced rat rhabdomyosarcoma established in culture (RMS 9-4/0), resistant to treatment with the chloronitrosourea, chlorozotocin (CZT) (R-lines). They were separated from the whole population of cells by a cloning procedure. Furthermore, we demonstrate that the cloning procedure by itself allows the isolation of tum- variant designated as C-lines. In both cases, the tum- phenotype was observed after s.c. injection of cells into syngeneic rats with a broad range of R9 or C8 cells (10(4) to 10(7). This characteristic was inherited in a stable manner. Athymic mice developed tumours of rat rhabdomyosarcoma origin when grafted with 10(5) cells. Immunization of rats with one R variant (R9) tum- protected the rats grafted with the parental RMS 9-4/0 cells against metastatic invasion of the lungs, but not against local tumour growth, and rats grafted with a CZT-resistant tum+ cell variant S4T (in vivo-derived) against its hepatic and pulmonary metastases, while the local tumour progressed as usual. Immunization of rats with one C variant (C8) tum- cells did not protect them against either metastases or local growth of the implanted tumours. Both R and C lines cells became progressively resistant to NK- and macrophage-induced cytotoxicity. Splenic lymphocyte transfer from immune rats into nude mice, i.e., the Winn test, showed a complete degree of protection against C8 or R9 tumour growth. We conclude that two different antigenicities were revealed, one common to R9 and C8 cells in relation with their selection procedure by repeated cloning. Another antigenicity appeared in the R9 line, selected by CZT-resistance. The anti R9 cell immunization against CZT-resistant tum+ S4T could argue in favour of CZT action in the acquisition of R9 cell antigenicity. More likely, an amplification of antigens rather than induction of a new antigen could explain the protection of anti R9 immunized rats against parental tumour metastases.

Full text

PDF
7

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boon T., Kellermann O. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc Natl Acad Sci U S A. 1977 Jan;74(1):272–275. doi: 10.1073/pnas.74.1.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chen T. R. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res. 1977 Feb;104(2):255–262. doi: 10.1016/0014-4827(77)90089-1. [DOI] [PubMed] [Google Scholar]
  3. Evans R. The immunological network at the site of tumor rejection. Biochim Biophys Acta. 1986 Aug 5;865(1):1–11. doi: 10.1016/0304-419x(86)90009-0. [DOI] [PubMed] [Google Scholar]
  4. Fidler I. J., Nicolson G. L. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst. 1976 Nov;57(5):1199–1202. doi: 10.1093/jnci/57.5.1199. [DOI] [PubMed] [Google Scholar]
  5. Fioretti M. C., Bianchi R., Romani L., Bonmassar E. Drug-induced immunogenic changes of murine leukemia cells: dissociation of onset of resistance and emergence of novel immunogenicity. J Natl Cancer Inst. 1983 Dec;71(6):1247–1251. [PubMed] [Google Scholar]
  6. Frost P., Kerbel R. S. On a possible epigenetic mechanism(s) of tumor cell heterogeneity. The role of DNA methylation. Cancer Metastasis Rev. 1983;2(4):375–378. doi: 10.1007/BF00048568. [DOI] [PubMed] [Google Scholar]
  7. Giavazzi R., Scholar E., Hart I. R. Isolation and preliminary characterization of an Adriamycin-resistant murine fibrosarcoma cell line. Cancer Res. 1983 May;43(5):2216–2222. [PubMed] [Google Scholar]
  8. Goodenow R. S., Vogel J. M., Linsk R. L. Histocompatibility antigens on murine tumors. Science. 1985 Nov 15;230(4727):777–783. doi: 10.1126/science.2997918. [DOI] [PubMed] [Google Scholar]
  9. Katzav S., Segal S., Feldman M. Metastatic capacity of cloned T10 sarcoma cells that differ in H-2 expression: inverse relationship to their immunogenic potency. J Natl Cancer Inst. 1985 Aug;75(2):307–318. [PubMed] [Google Scholar]
  10. Laval F. Repair of methylated bases in mammalian cells during adaptive response to alkylating agents. Biochimie. 1985 Mar-Apr;67(3-4):361–364. doi: 10.1016/s0300-9084(85)80081-x. [DOI] [PubMed] [Google Scholar]
  11. Nardelli B., Contessa A. R., Romani L., Sava G., Nisi C., Fioretti M. C. Immunogenic changes of murine lymphoma cells following in vitro treatment with aryl-triazene derivatives. Cancer Immunol Immunother. 1984;16(3):157–161. doi: 10.1007/BF00205422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Olsson L., Forchhammer J. Induction of the metastatic phenotype in a mouse tumor model by 5-azacytidine, and characterization of an antigen associated with metastatic activity. Proc Natl Acad Sci U S A. 1984 Jun;81(11):3389–3393. doi: 10.1073/pnas.81.11.3389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pauwels C., Rebischung J. L., Jasmin C., Poupon M. F. Enhanced cloning efficiency of murine rhabdomyosarcoma cells after chlorozotocin treatment: relationship with enhanced lung metastasis. J Natl Cancer Inst. 1985 Apr;74(4):817–820. [PubMed] [Google Scholar]
  14. Pot-Deprun J., Poupon M. F., Sweeney F. L., Chouroulinkov I. Growth, metastasis, immunogenicity, and chromosomal content of a nickel-induced rhabdomyosarcoma and subsequent cloned cell lines in rats. J Natl Cancer Inst. 1983 Dec;71(6):1241–1245. [PubMed] [Google Scholar]
  15. Poupon M. F., Pauwels C., Jasmin C., Antoine E., Lascaux V., Rosa B. Amplified pulmonary metastases of a rat rhabdomyosarcoma in response to nitrosourea treatment. Cancer Treat Rep. 1984 May;68(5):749–758. [PubMed] [Google Scholar]
  16. Price J. E., Syms A. J., Wallace J. S., Fleming K. A., Tarin D. Cellular immortality, clonogenicity, tumorigenicity and the metastatic phenotype. Eur J Cancer Clin Oncol. 1986 Mar;22(3):349–355. doi: 10.1016/0277-5379(86)90404-9. [DOI] [PubMed] [Google Scholar]
  17. Salmon S. E., Hamburger A. W., Soehnlen B., Durie B. G., Alberts D. S., Moon T. E. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med. 1978 Jun 15;298(24):1321–1327. doi: 10.1056/NEJM197806152982401. [DOI] [PubMed] [Google Scholar]
  18. Sweeney F. L., Pot-Deprun J., Poupon M. F., Chouroulinkov I. Heterogeneity of the growth and metastatic behavior of cloned cell lines derived from a primary rhabdomyosarcoma. Cancer Res. 1982 Sep;42(9):3776–3782. [PubMed] [Google Scholar]
  19. Van Pel A., Vessière F., Boon T. Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. J Exp Med. 1983 Jun 1;157(6):1992–2001. doi: 10.1084/jem.157.6.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Van Waes C., Urban J. L., Rothstein J. L., Ward P. L., Schreiber H. Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells. J Exp Med. 1986 Nov 1;164(5):1547–1565. doi: 10.1084/jem.164.5.1547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. WINN H. J. Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J Immunol. 1961 Feb;86:228–239. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES